Harmony Biosciences Holdings (HRMY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Harmony Biosciences Holdings (HRMY) has a cash flow conversion efficiency ratio of 0.030x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($27.76 Million) by net assets ($910.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HRMY net asset quality index to measure how much of total assets are equity-financed.
Harmony Biosciences Holdings - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Harmony Biosciences Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Harmony Biosciences Holdings's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Harmony Biosciences Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harmony Biosciences Holdings ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Systemair AB
ST:SYSR
|
0.073x |
|
Poly Medicure Limited
NSE:POLYMED
|
0.029x |
|
Chin Hin Group Bhd
KLSE:5273
|
0.088x |
|
Winpak Ltd.
TO:WPK
|
0.014x |
|
Qingdao Gon Technology Co Ltd
SHE:002768
|
0.007x |
|
InfoVision Optoelectronics Kunshan Co Ltd
SHG:688055
|
-0.009x |
|
Lier Chemical Co Ltd
SHE:002258
|
0.070x |
|
Anand Rathi Wealth Limited
NSE:ANANDRATHI
|
0.010x |
Annual Cash Flow Conversion Efficiency for Harmony Biosciences Holdings (2018–2025)
The table below shows the annual cash flow conversion efficiency of Harmony Biosciences Holdings from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Harmony Biosciences Holdings worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $870.22 Million | $348.20 Million | 0.400x | +19.98% |
| 2024-12-31 | $659.15 Million | $219.82 Million | 0.333x | -29.01% |
| 2023-12-31 | $466.99 Million | $219.39 Million | 0.470x | +31.00% |
| 2022-12-31 | $402.84 Million | $144.47 Million | 0.359x | -32.14% |
| 2021-12-31 | $186.51 Million | $98.56 Million | 0.528x | +1820.38% |
| 2020-12-31 | $97.18 Million | $-2.98 Million | -0.031x | -100.47% |
| 2019-12-31 | $-11.59 Million | $-75.44 Million | 6.512x | +1468.26% |
| 2018-12-31 | $81.53 Million | $-38.80 Million | -0.476x | -- |
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that … Read more